Hydroxychloroquine in dermatology: New perspectives on an old drug

  title={Hydroxychloroquine in dermatology: New perspectives on an old drug},
  author={C. Y. Chew and A. Mar and M. Nikpour and A. Saracino},
  journal={Australasian Journal of Dermatology},
Hydroxychloroquine is an age‐old drug whose use as an immunomodulatory agent with a low side‐effect profile continues to expand. We present a review of this drug including recently updated prescribing recommendations and a summary of its clinical application in dermatology. A maximum daily dose of 5.0 mg/kg based on actual body weight and no greater than 400 mg is advised in order to reduce the risk of retinopathy, which is potentially permanent and has an estimated prevalence of 7.5% at 5… Expand
Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure
Although decreased visual acuity is an infrequent symptom, ophthalmologists should be aware of the possibility of HCQ concentration enrichment and consider minimizing HCQ use when a child with renal hypofunction seeks treatment for shortsightedness. Expand
Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine
A review of reformulation efforts to date of chloroquine and hydroxychloroquine highlights issues in experimental designs leading to ambiguity regarding nanoformulation improvements and lack of thorough pharmacokinetics and safety evaluation, as well as recommendations for future formulation efforts. Expand
La hidroxicloroquina como fármaco fundamental en dermatología y su papel controvertido en la COVID-19
Hydroxychloroquine is an antimalarial drug with immunomodulatory, anti-inflammatory, antibacterial, and antiviral properties that was widely prescribed both to prevent and to treat COVID-19 caused by SARS-CoV-2. Expand
Drug-Induced Neutropenia During Treatment of Non-Neoplastic Dermatologic Diseases: A Review
The majority of patients recovered after drug discontinuation and supportive management including antibiotics and granulocyte colony-stimulating factor, but fatal cases were reported. Expand
A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine
A case of acute haemolysis leading to admission in intensive care unit and renal failure in a patient with uncovered G6PD deficiency is reported and Belgian national treatment guidelines recommend the use of HCQ in mild to severe COVID-19 disease. Expand
Enantiomers of Chloroquine and Hydroxychloroquine Exhibit Different Activities Against SARS-CoV-2 in vitro, Evidencing S-Hydroxychloroquine as a Potentially Superior Drug for COVID-19
It is recommended that future clinical studies should employ S-HCQ, substantially free of the R-enantiomer, to potentially improve the therapeutic index for the treatment of COVID-19 over the racemic CQ and HCQ. Expand
In-line treatments and clinical initiatives to fight against COVID-19 outbreak
The article mainly focused on the development and possible application of various FDA approved drugs, including chloroquine, remdesivir, favipiravir, nefamostate mesylate, penciclovir, nitazoxanide, ribavirin etc., vaccines under development and various registered clinical trials exploring different therapeutic measures for the treatment of COVID-19. Expand
Structural insight to hydroxychloroquine-3C-like proteinase complexation from SARS-CoV-2: inhibitor modelling study through molecular docking and MD-simulation study
Hydroxychloroquine is used to perform molecular docking followed by MD-simulation studies of HCQ and modelled some ligand molecules with SARS-CoV-2-main protease which reveals the structural organization of the active site residues and presence of a conserve water-mediated catalytic triad that helps in the recognition of Mod-I/II ligand molecule. Expand


Updated recommendations on the use of hydroxychloroquine in dermatologic practice
&NA; Hydroxychloroquine has unique immunomodulatory properties and an attractive adverse effect profile. Over the past 10 years, research has led to significant updates in clinical recommendationsExpand
Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision).
Recommendations on screening for chloroquine and hydroxychloroquine retinopathy are revised in light of new information about the prevalence of toxicity, risk factors, fundus distribution, and effectiveness of screening tools. Expand
New concepts in antimalarial use and mode of action in dermatology
The different antimalarials used within dermatology through their pharmacologic properties and mechanism of action, as well as indicating their clinical uses are highlighted. Expand
Screening for hydroxychloroquine retinopathy
Ophthalmic screening is recommended in patients with known retinal disease or visual impairment; with renal or liver impairment; over 60 years old; receiving a daily dose greater than 6.5mg/kg; or who have received an accumulated dose above 500 g. Expand
Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature.
HCQ should probably be maintained throughout pregnancy in patients with SLE and it does not seem necessary to advise against breastfeeding. Expand
The role of hydroxychloroquine in the treatment of lichen planopilaris: A retrospective case series and review
Hydroxychloroquine was found to be a reasonable therapeutic choice in LPP and physician rated response was documented. Expand
Treatment of urticarial vasculitis: A systematic review
Biologicals, including omalizumab, as well as corticosteroids, cyclophosphamide, dapsone, mycophenolate mofetil, plasmapheresis, colchicine, hydroxychloroquine, intravenous immunoglobulin, nonsteroidal anti‐inflammatory drugs, and cyclosporine, can be effective for both skin and systemic symptoms in patients with UV. Expand
Low-dose hydroxychloroquine is as effective as phlebotomy in treatment of patients with porphyria cutanea tarda.
  • A. Singal, C. Kormos-Hallberg, +4 authors K. Anderson
  • Medicine
  • Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • 2012
Hydxychloroquine, 100 mg orally, twice weekly, is as effective and safe as phlebotomy in patients with PCT, although noninferiority was not established. Expand
Clinical Efficacy and Safety of Methotrexate versus Hydroxychloroquine in Preventing Lichen Planopilaris Progress: A Randomized Clinical Trial
Methotrexate was more effective than hydroxychloroquine in treating refractory lichen planopilaris and the following symptoms/signs showed significant improvements in frequency and/or severity after intervention. Expand
Comparative efficacy of hydroxychloroquine and griseofulvin in the treatment of lichen planus
In this study both hydroxychloroquine and griseofulvin showed clinical improvement but hydroxy chloroquine showed a relatively better response than griseefulvin in the treatment of LP. Expand